Phase 2
N=182
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Unresectable Stage III · Stage IV Melanoma
Bottom Line
View on ClinicalTrials.gov: NCT01136967 ↗Enrolled (actual)
182
Serious AEs
41.2%
Results posted
Mar 2016
Primary outcome: Primary: Objective Response Rate (ORR) — 8.6; 9.0 Percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Lenvatinib (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Eisai Inc.
- Primary completion
- Apr 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Objective Response Rate (ORR) |
8.6; 9.0 | — |
| SECONDARY Progression Free Survival (PFS) |
3.7; 1.8; 3.7; 2.3 | — |
| SECONDARY Overall Survival (OS) |
8.9; 6.3 | — |
| SECONDARY Disease Control Rate (DCR) |
52.7; 34.8; 64.5; 48.3 | — |
| SECONDARY Clinical Benefit Rate (CBR) |
31.2; 14.6; 33.3; 20.2 | — |
| SECONDARY Number of Participants With Adverse Events (AEs)/ Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib |
93; 89; 39; 36 | — |
| SECONDARY Change From Baseline in the Concentration of Clinical Biomarkers in Whole Blood |
-1015.69; -832.29; -923.82; -947.00; -1225.322; -1100.235 | — |
| SECONDARY Summary of Plasma Concentration of Lenvatinib |
0; 0; 229.6; 287.6; 56.8; 71.9 | — |
Summary
The purpose of this study is to assess the objective response rate of lenvatinib in previously treated participants with American Joint Committee on Cancer (AJCC) unresectable Stage III or Stage IV melanoma and disease progression.
Eligibility Criteria
Inclusion Criteria
- Histologically confirmed diagnosis of melanoma.
- Unresectable Stage III or Stage IV melanoma.
- Evidence of disease progression according to RECIST 1.1 on prior regimen.
- Participants with brain metastases will be eligible if they have undergone complete surgical excision and are more then 1 month post surgery with no radiographic evidence of disease recurrence in the brain or have undergone stereotactic radio surgery (gamma knife procedure) and are more then 1 month post procedure and with no radiographic evidence of disease progression in the brain; and are asymptomatic, and discontinued corticosteroid treatment at least 30 days prior starting treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequately controlled blood pressure.
- Adequate renal function, bone marrow function, blood coagulation function, and liver function, as defined in the study protocol.
Exclusion Criteria
- Melanoma of intraocular origin.
- Leptomeningeal metastases or brain metastases except as for participants with brain metastases will be eligible if they have undergone complete surgical excision and are more then 1 month post surgery with no radiographic evidence of disease recurrence in the brain or have undergone stereotactic radio surgery (gamma knife procedure) and are more then 1 month post procedure and with no radiographic evidence of disease progression in the brain; and are asymptomatic, and discontinued corticosteroid treatment at least 30 days prior starting treatment.
- More than 2 prior systemic anticancer regimen treatments including immunotherapies for unresectable Stage III or Stage IV disease (if BRAF V600E mutation negative) or not previously treated with BRAF V600E-targeted therapy or received in the past more than 2 prior systemic anticancer regimen treatments, including immunotherapies, in addition to a BRAF-V600E-targeted therapy (if BRAF V600E mutation positive).
- Significant cardiovascular impairment.
- Bleeding disorder or a thrombotic disorder requiring anticoagulant therapy.
- Females who are pregnant or breastfeeding.
- Prolongation of QTc interval to greater than 480 msec.
- 24 hour urine protein greater than or equal to 1 gm.
- Active hemoptysis within 3 wks prior to the first dose of study drug.
Data sourced from ClinicalTrials.gov (NCT01136967). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.